USPTO serial 79244477
CURADIGM
Reviewed by CopyMark Law Group
Reg. 5796583Status 709
- Filing date
- Status date
- Registration date
- Jul 9, 2019
- Examiner
- BROWN, TRICIA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CURADIGM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Products for medical use especially for metabolic pathways, namely, enzyme substrates and enzyme inhibitors; products for medical use especially for the diagnosis and treatment of tumors, namely, diagnostic preparation for medical purposes for the diagnosis of tumors and therapeutic pharmaceutical preparations for medical purposes for the treatment of tumors and rare hepatic diseases; preparations for medical use especially for modifying the bioavailability of therapeutic agents, namely, lipidic and polymeric formulation for drug delivery in the nature of drug delivery agents in the form of nanoparticles, nanovesicles, particles, vesicles, dissolvable films, coatings for tablets and hydrogels that facilitate the delivery of pharmaceutical preparations; preparations for medical use especially for modifying liver functions, namely, pharmaceutical preparations for the treatment of liver diseases and disorders and pharmaceutical preparations to alter hepatic metabolization pathways; preparations for medical use for modifying the functions of the reticuloendothelial system, namely, pharmaceutical preparations for the treatment of reticuloendothelial system diseases and disorders and pharmaceutical preparations to alter reticuloendothelial system endocytosis pathways; preparations made with nanomaterials for the delivery of therapeutic agents, namely, drug delivery agents in the form of enterally, parenterally in the nature of intravenous, or topically administered nanomaterials that facilitate the delivery of pharmaceutical preparations; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use for the treatment of cancer, central nervous system disorders, cardiological, immunological, gastrointestinal, metabolic and infection diseases; enzymes for medical use; enzyme preparations for medical use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infection diseases; diagnostic products for medical use, namely, diagnostic preparations for medical purposes; drugs for medical use, namely, medical preparations for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infectious diseases; medicines for human medicine, namely, medical preparations for the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infectious diseases; tonics medicines, namely, medical herbal preparations; antibiotics; antiseptics; chemico-pharmaceutical products for the treatment of the treatment of cancer, central nervous system disorder, cardiological, immunological, gastrointestinal, metabolic and infection diseases; pharmaceutical products, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic substances for medical use, namely, dietetic foods adapted for medical purposes; remedies for human medicine, namely, natural remedy preparations for the treatment of gastrointestinal conditions, hormonal and chemical imbalances, and sleep disorders | SECTION 71 - CANCELLED | — |
| 010 | Surgical and medical apparatus and instruments especially for the diagnosis and treatment of tumors; Surgical and medical apparatus and instruments especially for monitoring and modifying metabolic functions; Apparatus for modifying the functions of the reticuloendothelial system, namely, medical apparatus and instruments for use in endovascular and cardiovascular procedures; Apparatus for modulating liver functions, namely, medical apparatus and instruments for use in measuring, quantifying and assessing liver health and oxygenation and perfusion apparatus in the nature of perfusion pumps for liver transplantation; Apparatus for the delivery of therapeutic or diagnostic agents, namely, medical apparatus and units for dosage, measuring and monitoring, in the nature of drug delivery devices and systems, and organ oxygenation and perfusion apparatus in the nature of perfusion pumps; Apparatus for modulating hepatic blood flow, namely, organ perfusion apparatus in the nature of perfusion pumps; Testing apparatus for medical use in the nature of medical diagnostic apparatus for testing cancer calls, DNA, organ oxygenation and blood sugar levels; Diagnostic apparatus for medical use for testing cancer calls, DNA, organ oxygenation and blood sugar levels | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, research and design especially in the field of nanomedicine, in the nature of nanotechnology applied to medicine; Biological research services; Bacteriological research services; Evaluations, estimates and research in scientific and technological fields provided by engineers and researchers, namely, conducting early evaluations in the field of new pharmaceuticals; Design and development of new products for third parties in the field of pharmaceutical preparations and diagnostic devices design; Technical research in the field of pharmaceutical project studies; Industrial analysis and research services, namely, biomedical research services; Chemical analysis; Chemical research; Chemistry services, namely, chemistry consultation; Surveying, namely, engineering work; Research and development of new products for others; Technical research in the field of pharmaceutical studies; Biological research, namely, radiobiology research, biological, pharmacokinetic, pharmacodynamic and immunological evaluation and toxicological evaluation; Medical research, namely, research in nanoscience and nanotechnology, especially applied to medicine | SECTION 71 - CANCELLED | — |
| 044 | Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by CURADIGM
- Other trademarks owned by NANOBIOTIX
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CURADIGM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 23, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 23, 2026 | C71T | CANCELLED SECTION 71 | — |
| Dec 27, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Feb 27, 2020 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Nov 15, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 29, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 29, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 9, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 9, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 3, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 23, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 17, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 17, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 3, 2019 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 15, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 15, 2019 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Mar 14, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 14, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 8, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 7, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 7, 2019 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 4, 2019 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 1, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 8, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 8, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 7, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 3, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 4, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 4, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 19, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 18, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 18, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 13, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 7, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 1, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |